Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
According to a recent study, bariatric surgery reduced incident cardiovascular disease and composite cardiovascular adverse outcomes by almost 50%.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.
Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.
Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia
COPD in 2025: Year in Review
FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector
Nephrology in 2025: Year in Review
1.
Nuclear missile workers are contracting cancer: They blame the bases
2.
Dietary Intervention Shows Promise in Blood Cancers
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
Childhood cancer survivors face new health problems later in life, study shows
5.
Hemihedral resection not necessary for neuroendocrine surgery after appendicitis
1.
Understanding the Importance of Knowing Your MCV Normal Range
2.
The Power of Salt Tablets: Unlocking Health Benefits Beyond Sodium
3.
Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights
4.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
5.
Case Study: Genomic Medicine in Precision Oncology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge